TXG10x Genomics, Inc.
Is the business good?
The checks split: nothing decisive, though margins widening.
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is TXG?
10x Genomics, Inc. earns −26% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 35 points below what the capital costs: growth destroys value
- Operating margin
- −14%
Operating margin · Health Information Services median 2.8% · 12 months to Q2 2026
- Share count, year on year
- +4.4%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 37%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −179% |
| FY2021 | −11% |
| FY2022 | −33% |
| FY2023 | −43% |
| FY2024 | −32% |
| FY2025 | −9.5% |
Details›
- Gross margin12 months to Q2 2026
- 70%
- Operating margin12 months to Q2 2026
- −14%
- Net margin12 months to Q2 2026
- −12%
- Free cash flow margin
- 20%
- R&D as % of revenue
- 37%
- Revenue, trailing twelve months
- $617M
- Free cash flow, trailing twelve months
- $121M
- Net income, trailing twelve months
- −$75M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −26%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Health Information Services
Ranks #16 of 20 by RyuScore